Business Context and Reporting Period
Company: Mesoblast Limited (Mesoblast)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Nine months ended March 31, 2018
Business Overview: Mesoblast is a global biotechnology company developing regenerative medicine products based on mesenchymal lineage adult stem cells. The company is in the clinical-stage phase, focusing on late-stage product candidates for cardiovascular, orthopedic, immunologic, and oncologic conditions. It operates as a single segment.
Key Financial Metrics
| Metric (in thousands USD) | Nine Months Ended March 31, 2018 |
Nine Months Ended March 31, 2017 |
|---|---|---|
| Total Revenue | $15,641 | $1,846 |
| Net Loss | $(14,456) | $(49,633) |
| Loss Per Share (Basic & Diluted) | $(0.0312) | $(0.1275) |
| Operating Cash Flow | $(54,824) | $(72,036) |
| Cash and Cash Equivalents (End of Period) | $59,539 | $69,122 |
| Total Debt (Borrowings) | $31,422 | $0 |
| Accumulated Deficit | $(359,358) | $(317,720) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 747% (from $1.8M to $15.6M). This was primarily driven by $12.8M in milestone revenue, largely due to a $11.8M payment from a patent license agreement with TiGenix NV (including a $5.9M upfront payment and $5.9M due within 12 months). Commercialization revenue also rose to $2.5M from royalties on TEMCELL sales in Japan.
- Reduced Net Loss: The net loss decreased significantly by 71% (from $49.6M to $14.5M). This improvement was driven by the revenue spike and a non-cash income tax benefit of $29.7M resulting from the remeasurement of deferred tax balances following the U.S. Tax Cuts and Jobs Act (reducing the corporate tax rate from 35% to 21%).
- Debt Financing: The company entered a $75.0M credit facility with Hercules Capital, Inc. on March 6, 2018, drawing the first tranche of $35.0M. This introduced $31.4M in borrowings on the balance sheet, compared to zero debt in the prior period.
- Expense Management: Manufacturing commercialization expenses decreased by 69% (from $10.9M to $3.4M) due to reduced production runs as clinical supply demands were met. Research and development expenses increased by 13% (from $43.0M to $48.4M) due to clinical advancements in Tier 1 products.
Guidance, Outlook, and Risks
- Going Concern Uncertainty: Management has identified a material uncertainty regarding the company's ability to continue as a going concern. Viability depends on securing non-dilutive funding (partnerships/debt) or equity financing, alongside cost containment strategies. A discretionary equity facility of up to A$120M (US$90M) remains available for 15 months.
- Clinical Progress:
- MSC-100-IV (aGVHD): Phase 3 trial met its primary endpoint (Day 28 overall response rate of 69% vs. 45% historical control). The company believes this supports a filing for accelerated FDA approval.
- MPC-150-IM (Heart Failure): Phase 3 trial enrollment is ongoing; the Data Monitoring Committee recommended continuation without modification.
- MPC-06-ID (Low Back Pain): Phase 3 trial enrollment completed with 404 patients.
- Strategic Partnerships: Entered a partnership with Cartherics Pty Ltd to develop allogeneic CAR-T cells for solid cancers, funded by Australian government grants.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, regulatory delays, reliance on third-party manufacturers (Lonza), and the potential for the company to be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $59.5M cash balance against the $54.8M operating cash burn for the nine-month period to assess immediate liquidity needs.
- Debt Covenants: Review the specific financial covenants and interest rate terms (currently ~9.70% floating) of the $75M Hercules Capital facility.
- TiGenix Milestone Sustainability: Confirm the timing and certainty of the remaining $5.9M payment from TiGenix and the potential for future regulatory milestones.
- Regulatory Pathway: Monitor FDA interactions regarding the accelerated approval pathway for MSC-100-IV following the successful Phase 3 results.
- Going Concern Status: Track progress on commercial partnerships and equity raises to ensure the "material uncertainty" regarding going concern status is resolved.